LEXINGTON, Mass., July 3, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that on July 9, 2013 the Company will participate in the Piper Jaffray Catalyst Symposium in Boston and on July 10, 2013, Dan Passeri, Chief Executive Officer, will present a corporate overview at the 8th Annual JMP Securities Healthcare Conference in New York City. Details of these two events are as follows:
|Piper Jaffray Catalyst Symposium: Emerging Talent in BioPharma|
|Date: Tuesday, July 9, 2013|
|Location: Ritz-Carlton Boston Common, Boston, MA|
|8th Annual JMP Securities Healthcare Conference in New York City|
|Date: Wednesday, July 10, 2013|
|Location: The St. Regis in New York, NY|
|Presentation Time: 1:00 pm ET|
A corresponding webcast of the JMP presentation can be accessed by visiting:
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.
CONTACT: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations 617-503-6605 email@example.com Michael P. Gray Chief Financial Officer Curis, Inc. 617-503-6632 firstname.lastname@example.org